Lupin Presents Phase 3 Data for Solosec(R) (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis

Results presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting Single-dose treatment with Solosec® resulted in a highly statistically significant response rate, or microbiological cure, in 92-95%... Biopharmaceuticals Lupin Pharmaceuticals, Solosec, secnidazole, trichomoniasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news